Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexidem versus BCG after transurethral resection for superficial papillary bladder cancer
2004-003699-13Phase 2Active
- Sponsor
- IDM Pharma
- Start
- May 2005
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in bladder cancer comparing Bexidem with BCG comparator (2 arms). Primary endpoints: Frequent Immunotherapy-Linked Adverse Events and recurrence-free survival. Started May 2005; status: active.
02
Drugs
Bexidembcg vaccine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2004-003699-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003699-13.